Table 3.

Anti-MI Therapeutics via targeting SUMOylation.

Therapeutics/regents	SUMOylated protein/substrate	SUMO proteases	Function	Phase of research	References
Moderate hypothermia	/	SUMO1	enhancing SUMOylation and attenuating MI/R injury	Clinical trial	(123)
Zinc	Drp1	/	Regulating mitochondrial autophagy and reducing MI/R injury	Preclinical study	(67)
Luteolin	SERCA2a	SUMO1	Stabilizing SERCA2a	Preclinical study	(114, 115)
Ginkgolic acid	PML/Pin1/TGF-β1	SUMO1	Inhibiting cardiac fibrosis	Preclinical study	(124)
Irisin	HDAC4	SUMO1	Improving degradation of HDAC4	Preclinical study	(91)
Mdivi-1	Drp1	SENP3	Attenuating mitochondrial abnormality and cardiac injury	Preclinical study	(65)
TAK-981	/	SUMO molecule	Inhibiting SUMOylation	Phase 1 clinical trial	(29)
PIAS1	PPAR-γ	SUMO E3 ligases	Inhibiting apoptosis and inflammation	Preclinical study	(86)